Isernhagen, Germany

Henning Weigt


 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Henning Weigt: Innovator in BCRP Inhibitors

Introduction

Henning Weigt is a notable inventor based in Isernhagen, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target multidrug resistance in cancer and HIV treatments.

Latest Patents

Weigt holds a patent for "4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments." This invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, which are designed to inhibit the BCRP protein. The compounds exhibit a high inhibitory activity against BCRP, which can enhance the efficacy of drugs affected by this multidrug resistance modulator. This discovery has promising implications for improving treatment outcomes in cancer and HIV patients.

Career Highlights

Henning Weigt is associated with Scandion Oncology A/S, where he continues to advance research in the field of oncology. His work focuses on developing innovative solutions to combat drug resistance, which is a significant challenge in effective cancer treatment.

Collaborations

Weigt collaborates with Steffen Rump, contributing to the advancement of their shared goals in pharmaceutical innovation.

Conclusion

Henning Weigt's contributions to the development of BCRP inhibitors represent a significant advancement in therapeutic treatments for cancer and HIV. His innovative work continues to pave the way for improved patient outcomes in the fight against multidrug resistance.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…